Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc exhibits a highly leveraged capital structure with total liabilities of CAD 1,848,210 and total equity of CAD -1,629,430, resulting in a negative net worth. The company's liquidity position is weak, as indicated by a current ratio of 0.02, suggesting significant short-term financial stress. The enterprise value to revenue ratio of 66.16 is well above the typical range for pharmaceutical firms, reflecting a premium valuation despite negative operating performance. Profitability metrics reveal a challenging operating environment. The company reported a net loss of CAD 332,770 and an operating loss of the same amount, with a negative return on assets of -1.52%. These figures contrast sharply with the industry's median profitability metrics, which typically show positive returns for firms in the Pharmaceuticals & Medical Research sector. The gross profit margin of 70.5% is relatively strong, but this is offset by high operating expenses that erode profitability. The company's revenue is concentrated in a single product line, the Eleotin formulations, which are marketed as natural remedies for metabolic disorders. There is no disclosed geographic diversification beyond North America, and the company's operations are entirely focused on this region. This concentration increases vulnerability to regulatory changes or market shifts in the natural health product segment. Growth prospects appear constrained. The company reported revenue of CAD 782,080 in the latest period, but there is no indication of revenue growth in the historical data. The outlook for the current fiscal year suggests continued financial pressure, with no clear path to profitability. The negative free cash flow of CAD -287,810 indicates that the company is not generating sufficient cash to fund operations or reinvest in the business. The risk assessment highlights significant financial vulnerabilities. The company's liquidity risk is rated as medium, with a negative net cash position after subtracting total debt. The dilution risk is currently low, but the negative equity position increases the potential for future dilution if the company requires additional capital. The risk assessment also flags the company's inability to meet short-term obligations without external financing. Recent filings and transcripts indicate that the company is actively engaged in research and development for new formulations. However, there is no indication of new product launches or regulatory approvals in the near term. The company's reliance on a limited product portfolio and the absence of recent revenue-generating events suggest that it is in a development phase rather than a growth phase.